BioPorto Diagnostics (BIOPOR.CO) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

BioPorto Diagnostics is a Copenhagen-based company focused on improving kidney health by addressing the critical unmet need for early detection of Acute Kidney Injury (AKI). Its core achievement is the development and commercialization of NGAL-based diagnostic tests, including the FDA-cleared ProNephro AKI for pediatric risk assessment and The NGAL Test™ for broader use. The company's strategy centers on expanding the clinical utility and geographic adoption of its NGAL platform through direct commercialization and strategic partnerships, such as its distribution agreement with Roche Diagnostics.

NephrologyAcute Kidney Injury

Technology Platform

Platform built around the NGAL (Neutrophil Gelatinase-Associated Lipocalin) biomarker, with proprietary assays for detection in blood and urine across clinical chemistry (automated analyzers) and ELISA (research) formats.

Opportunities

The primary opportunity lies in expanding FDA clearance for NGAL-based testing into the large adult AKI population, which would dramatically increase the addressable market.

Furthermore, deepening clinical utility in high-risk settings like cardiac surgery, ICU, and transplant through guideline inclusion can drive sustained test adoption and revenue growth.

Risk Factors

Key risks include failure to secure FDA clearance for adult indications, slow clinical adoption and reimbursement challenges despite regulatory success, and competition from alternative biomarkers like NephroCheck®.

The company's financial sustainability also depends on managing cash burn and accessing capital until profitability is achieved.

Competitive Landscape

BioPorto competes directly with Astute Medical/Abbott's NephroCheck® (TIMP-2*IGFBP7) in the AKI biomarker space and, more broadly, with the entrenched standard of care (serum creatinine). Its competitive advantages include first FDA clearance for pediatrics, a strategic distribution deal with Roche, and a deep clinical evidence base for NGAL.

More companies in Diagnostics & Precision Medicine →More companies in Denmark →